Patent ID: 9358282
Filing Date: 2016-06-07
CPC Classification: A61K,A61P,C07K,C12N

Claim Text:
1. An agent for retargeting T cells to cancer cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the cancer cells, wherein the targeting moiety is Rituximab or Cetuximab; (ii) a T cell epitope capable of eliciting a T cell response in a subject, wherein the T cell epitope is NLVPMVATV (SEQ ID NO: 21), and (iii) a peptide linker comprising a peptide cleavage site cleavable by a tumor associated protease and wherein the linker can be selectively cleaved by the tumor associated protease to release the T cell epitope in the vicinity of, and outside of, the cancer cell.